155 related articles for article (PubMed ID: 31209620)
21. Role of magnetic resonance diffusion-weighted imaging in evaluating response after chemoembolization of hepatocellular carcinoma.
Yuan Z; Ye XD; Dong S; Xu LC; Xu XY; Liu SY; Xiao XS
Eur J Radiol; 2010 Jul; 75(1):e9-14. PubMed ID: 19540083
[TBL] [Abstract][Full Text] [Related]
22. Transarterial chemoembolization in pancreatic adenocarcinoma with liver metastases: MR-based tumor response evaluation, apparent diffusion coefficient (ADC) patterns, and survival rates.
Vogl TJ; Mohamed SA; Albrecht MH; Gruber-Roh T; Lin H; Nour Eldin NEA; Bednarova I; Naguib NN; Panahi B
Pancreatology; 2018 Jan; 18(1):94-99. PubMed ID: 29221632
[TBL] [Abstract][Full Text] [Related]
23. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
[TBL] [Abstract][Full Text] [Related]
24. Robust evidence for long-term survival with
Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
[TBL] [Abstract][Full Text] [Related]
25. Transarterial Radioembolization Following Chemoembolization for Unresectable Hepatocellular Carcinoma: Response Based on Apparent Diffusion Coefficient Change is an Independent Predictor for Survival.
Klompenhouwer EG; Dresen RC; Verslype C; Laenen A; Bonne L; Vandecaveye V; Maleux G
Cardiovasc Intervent Radiol; 2018 Nov; 41(11):1716-1726. PubMed ID: 29872894
[TBL] [Abstract][Full Text] [Related]
26. Diffusion-weighted magnetic resonance imaging to predict response of hepatocellular carcinoma to chemoembolization.
Chung JC; Naik NK; Lewandowski RJ; Deng J; Mulcahy MF; Kulik LM; Sato KT; Ryu RK; Salem R; Larson AC; Omary RA
World J Gastroenterol; 2010 Jul; 16(25):3161-7. PubMed ID: 20593501
[TBL] [Abstract][Full Text] [Related]
27. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
Marugami N; Tanaka T; Kitano S; Hirohashi S; Nishiofuku H; Takahashi A; Sakaguchi H; Matsuoka M; Otsuji T; Takahama J; Higashiura W; Kichikawa K
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):638-46. PubMed ID: 19238482
[TBL] [Abstract][Full Text] [Related]
28. Chemoembolization for hepatocellular carcinoma: 1-month response determined with apparent diffusion coefficient is an independent predictor of outcome.
Vandecaveye V; Michielsen K; De Keyzer F; Laleman W; Komuta M; Op de beeck K; Roskams T; Nevens F; Verslype C; Maleux G
Radiology; 2014 Mar; 270(3):747-57. PubMed ID: 24475816
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
30. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
[TBL] [Abstract][Full Text] [Related]
31. Comparison of intravoxel incoherent motion imaging, diffusion kurtosis imaging, and conventional DWI in predicting the chemotherapeutic response of colorectal liver metastases.
Zhang H; Li W; Fu C; Grimm R; Chen Z; Zhang W; Qiu L; Wang C; Zhang X; Yue L; Hu X; Guo W; Tong T
Eur J Radiol; 2020 Sep; 130():109149. PubMed ID: 32659615
[TBL] [Abstract][Full Text] [Related]
32. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases.
Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181
[TBL] [Abstract][Full Text] [Related]
33. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period.
Gruber-Rouh T; Naguib NN; Eichler K; Ackermann H; Zangos S; Trojan J; Beeres M; Harth M; Schulz B; Nour-Eldin A NE; Vogl TJ
Int J Cancer; 2014 Mar; 134(5):1225-31. PubMed ID: 23960002
[TBL] [Abstract][Full Text] [Related]
34. Can volumetric ADC measurement help predict response to Y90 radioembolization in HCC?
Vouche M; Salem R; Lewandowski RJ; Miller FH
Abdom Imaging; 2015 Aug; 40(6):1471-80. PubMed ID: 25412868
[TBL] [Abstract][Full Text] [Related]
35. Radioembolization Versus Bland Embolization for Hepatic Metastases from Small Intestinal Neuroendocrine Tumors: Short-Term Results of a Randomized Clinical Trial.
Elf AK; Andersson M; Henrikson O; Jalnefjord O; Ljungberg M; Svensson J; Wängberg B; Johanson V
World J Surg; 2018 Feb; 42(2):506-513. PubMed ID: 29167951
[TBL] [Abstract][Full Text] [Related]
36. Baseline and Early MR Apparent Diffusion Coefficient Quantification as a Predictor of Response of Unresectable Hepatocellular Carcinoma to Doxorubicin Drug-Eluting Bead Chemoembolization.
Kokabi N; Ludwig JM; Camacho JC; Xing M; Mittal PK; Kim HS
J Vasc Interv Radiol; 2015 Dec; 26(12):1777-86. PubMed ID: 26603497
[TBL] [Abstract][Full Text] [Related]
37. Relationship between KRAS mutation and diffusion weighted imaging in colorectal liver metastases; Preliminary study.
Gültekin MA; Türk HM; Beşiroğlu M; Toprak H; Yurtsever I; Yilmaz TF; Sharifov R; Uysal Ö
Eur J Radiol; 2020 Apr; 125():108895. PubMed ID: 32109834
[TBL] [Abstract][Full Text] [Related]
38. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
[TBL] [Abstract][Full Text] [Related]
39. The significance of transarterial chemoembolization combined with systemic chemotherapy for patients with KRAS wild-type unresectable metachronous colorectal carcinoma with liver metastases.
Yu Q; Zhang L; Fan S; Huang L; Wang X; Xindun C
J Cancer Res Ther; 2016 Dec; 12(Supplement):C205-C211. PubMed ID: 28230018
[TBL] [Abstract][Full Text] [Related]
40. Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases.
Bonifacio C; Viganò L; Felisaz P; Lopci E; Cimino M; Poretti D; Donadon M; Pedicini V; Procopio F; Chiti A; Balzarini L; Torzilli G
Eur J Surg Oncol; 2019 Mar; 45(3):347-352. PubMed ID: 30528892
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
